CompanyDeals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

CompanyDrug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Biogen's High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
CompanyDrug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

CompanyDeals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

CompanyDeals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

CompanyDrug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

CompanyDrug

Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies

CompanyDeals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

CompanyDrug

Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors

CompanyDrug

Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent
CompanyDeals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

CompanyDeals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal